In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics (BOLD), with a price target of $45. The company’s shares closed yesterday at $37.05.
Yang noted:
“We recently highlighted the DMD program (click here to see our slides). A Phase 1/2 clinical trail is expected to start in 4Q19 at Nationwide Children’s Hospital. Finally, management is evaluating out-licensing opportunities for the CASQ2-CPVT programs.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.1% and a 42.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Audentes Therapeutics with a $43.14 average price target, representing a 16.4% upside. In a report issued on April 26, H.C. Wainwright also maintained a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Based on Audentes Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $35.59 million. In comparison, last year the company had a GAAP net loss of $25.57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
